Name (Synonyms) | Correlation | |
---|---|---|
drug130 | Azithromycin (Azithro) Wiki | 1.00 |
drug1026 | Placebo for Azithromycin Wiki | 1.00 |
drug1027 | Placebo for Hydroxychloroquine Wiki | 1.00 |
drug1132 | Ravulizumab Wiki | 1.00 |
drug592 | Hydroxychloroquine (HCQ) Wiki | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
D055370 | Lung Injury NIH | 0.23 |
D011024 | Pneumonia, Viral NIH | 0.14 |
D013577 | Syndrome NIH | 0.13 |
D055371 | Acute Lung Injury NIH | 0.12 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.12 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.10 |
D011014 | Pneumonia NIH | 0.07 |
There is one clinical trial.
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult patients with Coronavirus Disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute respiratory distress syndrome. Patients will be randomly assigned to receive ravulizumab in addition to best supportive care (BSC) (2/3 of the patients) or BSC alone (1/3 of the patients). Best supportive care will consist of medical treatment and/or medical interventions per routine hospital practice.